Core Viewpoint - InnoCare Pharma (02577.HK) has successfully completed a placement of 20.7 million new H-shares at a price of HKD 75.58 per share, raising approximately HKD 1.5504 billion, which will enhance the company's financial strength and market competitiveness [1] Group 1 - The placement agreement conditions have been fully met, and the placement was completed on October 17, 2025 [1] - A total of 20.7 million new H-shares were issued, representing about 3.94% of the total issued H-shares and approximately 2.26% of the total issued shares after the placement [1] - The net proceeds from the placement are approximately HKD 1.5504 billion, which will further strengthen the group's financial position and support its long-term sustainable development [1]
英诺赛科(02577.HK)完成配售合共2070万股新H股